Skip to content

Study · Ex vivo tissue · 1998

10 results

Presence of growth hormone secretagogue receptor messenger ribonucleic acid in human pituitary tumors and rat GH3 cells.

Adams EF, Huang B, Buchfelder M, Howard A, Smith RG, Feighner SD, van der Ploeg LH, Bowers CY, Fahlbusch R

The Journal of clinical endocrinology and metabolism1 Feb 1998Cited by 28 (Europe PMC)

PMID9467586 (opens in a new tab)DOI10.1210/jcem.83.2.4597 (opens in a new tab)PepBankPUB-09467586
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In culture, GHRP‑2 strongly increased phosphatidylinositol hydrolysis in four of six human somatotropinomas, and two tumors were resistant.

    In plain wordsIn cultured pituitary tumor cells, GHRP‑2 triggered a strong response in four of six tumors. Two did not respond.

    Peptide
    GHRP-2
    Outcome
    IncreasePI hydrolysis response to GHRP-2 in cultured somatotropinomas
    Study

    humann = 6

    Primary cultures of human pituitary tumors
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In culture, four of the tumors exhibited strong responses to GHRP-2 in terms of both phosphatidylinositol (PI) hydrolysis and GH secretion, but two were resistant.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).
  2. 02LabEx vivo tissueActivity measurement

    In culture, GHRP‑2 strongly increased GH secretion in four of six human somatotropinomas, and two tumors were resistant.

    In plain wordsIn cultured pituitary tumor cells, GHRP‑2 raised growth hormone release in four of six tumors. Two did not respond.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion response to GHRP-2 in cultured somatotropinomas
    Study

    humann = 6

    Primary cultures of human pituitary tumors
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In culture, four of the tumors exhibited strong responses to GHRP-2 in terms of both phosphatidylinositol (PI) hydrolysis and GH secretion, but two were resistant.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

Studies that did not test the peptide alone8

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 03LabNot a test of GHRP-2 aloneEx vivo tissueMechanism

    RT-PCR did not detect GHS-R mRNA in eight functionless human pituitary tumors.

    In plain wordsIn tissue from eight human pituitary tumors without hormone activity, the receptor for GH-releasing peptides was not found.

    Peptide
    GHRP-2
    Outcome
    No significant changeGHS-R mRNA in functionless pituitary tumors
    Study

    humann = 8

    Human functionless pituitary tumors
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    RT-PCR failed to detect GHS-R mRNA in eight functionless human pituitary tumors.
    2 context sentences
    Summary · context
    A novel G11-protein-coupled receptor specific for synthetic GH-releasing peptides (GHRPs) has recently been cloned and sequenced.
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 04LabNot a test of GHRP-2 aloneEx vivo tissueMechanism

    Both subtypes of GH secretagogue receptor mRNA were detected in all six human pituitary somatotropinomas from patients with acromegaly.

    In plain wordsIn lab tests on removed pituitary tumors, the receptor that GH-releasing peptides act on was present in all six tumors tested.

    Peptide
    GHRP-2
    Outcome
    Not applicableGHS-R mRNA in somatotropinomas
    Study

    humann = 6

    Primary cultures of human pituitary tumors
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Both subtypes of GHS-R mRNA were detected in all six human pituitary somatotropinomas removed from patients with acromegaly.
    2 context sentences
    Summary · context
    A novel G11-protein-coupled receptor specific for synthetic GH-releasing peptides (GHRPs) has recently been cloned and sequenced.
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 05LabNot a test of GHRP-2 aloneEx vivo tissueMechanism

    RT-PCR showed no apparent difference in the type 1a and 1b receptor expression pattern between tumors that responded to GHRP‑2 and tumors that did not.

    In plain wordsIn cultured pituitary tumor cells, receptor levels looked the same in tumors that responded to GHRP‑2 and in those that did not.

    Peptide
    GHRP-2
    Outcome
    No significant changeGHS-R 1a and 1b expression in responsive versus nonresponsive tumors
    Study

    humann = 6

    Primary cultures of human pituitary tumors
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    In culture, four of the tumors exhibited strong responses to GHRP-2 in terms of both phosphatidylinositol (PI) hydrolysis and GH secretion, but two were resistant. There was no apparent difference in the type 1a and type 1b expression pattern, as judged by RT-PCR, between responsive and nonresponsive tumors.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 06LabNot a test of GHRP-2 aloneEx vivo tissueActivity measurement

    In culture, GH-releasing peptides, as a class, significantly stimulated prolactin secretion in two of three prolactinomas tested.

    In plain wordsIn cultured human prolactinoma cells, GH-releasing peptides as a group raised prolactin release in two of three tumors.

    Peptide
    GHRP-2
    Outcome
    IncreasePRL secretion in cultured prolactinomas with GHRPs
    Study

    humann = 3

    Primary cultures of human pituitary tumors
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    In contrast, prolactinomas were found to express the receptor and, in culture, significant stimulation of PRL secretion and PI hydrolysis occurred in two of three tumors tested.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 07LabNot a test of GHRP-2 aloneEx vivo tissueActivity measurement

    In culture, GH-releasing peptides, as a class, significantly stimulated phosphatidylinositol hydrolysis in two of three prolactinomas tested.

    In plain wordsIn cultured human prolactinoma cells, GH-releasing peptides as a group triggered a cell response in two of three tumors.

    Peptide
    GHRP-2
    Outcome
    IncreasePI hydrolysis in cultured prolactinomas with GHRPs
    Study

    humann = 3

    Primary cultures of human pituitary tumors
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    In contrast, prolactinomas were found to express the receptor and, in culture, significant stimulation of PRL secretion and PI hydrolysis occurred in two of three tumors tested.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  6. 08LabNot a test of GHRP-2 aloneEx vivo tissueMechanism

    Human pituitary prolactinomas were found to express the receptor for GH-releasing peptides (GHS-R).

    In plain wordsIn lab tests on human prolactinoma tissue, the receptor that GH-releasing peptides act on was present.

    Peptide
    GHRP-2
    Outcome
    Not applicableGHS-R expression in prolactinomas
    Study

    humann: not reported in source

    Human pituitary prolactinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    In contrast, prolactinomas were found to express the receptor and, in culture, significant stimulation of PRL secretion and PI hydrolysis occurred in two of three tumors tested.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  7. 09LabNot a test of GHRP-2 aloneIn vitro (cells)Mechanism

    The rat pituitary tumor cell line GH3 expressed GHS-R mRNA.

    In plain wordsIn rat pituitary tumor cells, the receptor for GH-releasing peptides was present.

    Peptide
    GHRP-2
    Outcome
    Not applicableGHS-R mRNA in GH3 cells
    Study

    ratn: not reported in source

    GH3 rat pituitary tumor cell line
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Similarly, the rat pituitary tumor cell line, GH3, was found to express GHS-R mRNA, although these cells also did not respond to GHRPs.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  8. 10LabNot a test of GHRP-2 aloneIn vitro (cells)Activity measurement

    GH3 cells did not respond to GH-releasing peptides, as a class, despite expressing GHS-R mRNA.

    In plain wordsIn rat pituitary tumor cells, GH-releasing peptides as a group caused no response, even though the receptor was present.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH3 cell response to GHRPs
    Study

    ratn: not reported in source

    GH3 rat pituitary tumor cell line
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Similarly, the rat pituitary tumor cell line, GH3, was found to express GHS-R mRNA, although these cells also did not respond to GHRPs.
    1 context sentence
    Summary · context
    Using RT-PCR, we looked for the presence in tumorous pituitary cells of messenger ribonucleic acid (mRNA) for this novel GH secretagogue receptor (GHS-R).

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.